Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Releases Interpretations Of Criminal Activities Associated With Counterfeit Drugs

This article was originally published in PharmAsia News

Executive Summary

At a recent press conference by China's State Council Information Office, top executives from the People's Supreme Court and Procuratorate introduced the background, procedures and main content on the interpretation draft of the law against counterfeit and inferior medicines. Officially enforced on May 27, the legal application seeks to improve the criteria for determining the crimes of: production and sale of counterfeit drugs that are seriously harmful to health; damaging consequences for physical injuries caused by fake medicines; healthcare institutions that knowingly apply or sell counterfeit or inferior drugs, and their responsibilities according to criminal investigation; and those who facilitate illegal sales by providing mailing and advertising services. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071838

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel